Close Menu

drug development

The new unit will be headquartered in San Diego and led by Arthur Levin, chief development officer of Denmark-based Santaris.

Arthur Levin

The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.

The two-for-one split of the firm's shares took place before the opening of the market today.

The cell lines were developed using Horizon's Genesis platform and will be added to the firm's X-Man cell models.

Looking to support local industry and nurture Ireland's economic recovery, University College Dublin and Trinity College Dublin will combine their existing programs in tech transfer, enterprise development, industry relations, and post-graduate entrepreneurial education, largely in the area of life sciences.

The South African non-profit organization will team with the Malaysian pharmacogenomics firm to develop biomarker assays for the prediction of toxicity of existing and new drug compounds.

The goal of the project is to build a dynamic model of liver function in rats and humans that will account for effects of genetic variations and other variables, such as patient gender, age, behavioral traits, and environmental factors.

Snippets: Mar 11, 2009

Premium

Chronix Biomedical, Rosetta Genomics, National Institute of General Medical Sciences, National Center for Genome Resources, Beyond Batten Disease Research Foundation, and more ...

Chronix Biomedical said that the current study confirms its previous research showing that CNAs can identify the presence of certain diseases in blood samples months to years before clinical symptoms appear.

Pages

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.